~ Feb 09 The Cholesterol Controversy - References


1. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. J Lipid Res. 2004 Sep;45(9):1583-93.

2. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res. 2005 Feb;46(2):179-90.

3. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J Lipid Res. 2005 Oct;46(10):2037-51.

4. Steinberg D. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it—almost. J Lipid Res. 2006 Jan;47(1):1-14.

5. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res. 2006 Jul;47(7):1339-51.

6. Fleissig J. Uber die bisher als Riesenzellensarkome (Myelome) bezeichneten Granulationsgeschwulste der Sehnenschiden. Dtsch Z Chir. 1913;122:239-65.

7. Bailey CH. Observations on cholesterol-fed guinea pigs. Proc Soc Exper Biol. 1915;13:60-2.

8. Anitschkow N. Ueber die experimentelle Atherosklerose der Aorta beim Meerschwinchen. Beitr Pathol Anat. 1922;70:265-81.

9. Chalatow S. Bemerkungen an den Arbeiten uber Cholesterinsteatose. Virchows Arch A Pathol Anat Histol. 1929;272:691-708.

10. Anitschkow N. Einige Ergebnisse der experimentellen Atherosklerosforschung. Verhandlungen den Deutschen Pathologischen Gesellschaft. 1925;20:149-54.

11. Clarkson TB. Animal models of atherosclerosis. Adv Vet Sci Comp Med. 1972;16:151-73.

12. Lehzen G, Knauss K. Ueber Xanthoma multiplex planum, tuberosum, mollusciformis. Virchows Arch A Pathol Anat Histol. 1889;116:85-104.

13. Müller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med. 1939; 64:675-700.

14. Keys AC. Aravanis HW, Blackburn FS, et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40–59 in seven countries. Acta Med Scand. 1966;460(Suppl.):1-392.

15. Olson F, Michaels G, Partridge JW, et al. The use of formula diets administered via polyethylene tube or orally for constant intake (balance) studies. J Clin Nutr. 1953 Jan;1(2):134-9.

16. Ahrens EH, Jr, Dole VP, Blankenhorn DH. The use of orally-fed liquid formulas in metabolic studies. Am J Clin Nutr. 1954 Sep;2(5):336-42.

17. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. Acta Med Scand Suppl. 1966;466:1-92.

18. Kiecolt-Glaser JK, Belury MA, Porter K, et al. Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. Psychosom Med. 2007 Apr;69(3):217-24.

19. US Health Resources Administration. A comparison of levels of serum cholesterol of adults 18-74 years of age in the United States in 1960-62 and 1971-74. Vital & Health Statistics of The National Center for Health Statistics, US Department of Health and Education Welfare. 1977 Feb;22(5).

20. Available at: http://www.cdc.gov/nchs/data/statab/dx196067.pdf. Accessed September 29, 2008.

21. Higgins M, Thom T. Trends in CHD in the United States. Int J Epidemiol. 1989;18(3 Suppl 1):S58-66.

22. Anon. Diet and the possible prevention of coronary atheroma; a council statement. JAMA. 1965 Dec 6;194(10):1149-50.

23. Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science. 1950 Feb 17;111(2877):166-71.

24. Gofman JW. Serum lipoproteins and the evaluation of atherosclerosis. Ann NY Acad Sci. 1956 Nov 16;64(4):590-5.

25. Dobbin EV, Gofman HF, Jones HC, Lyon L, Young C. The Low-Fat, Low-Cholesterol Diet. Garden City, NY: Doubleday; 1951.

26. Steinberg D. Progress, prospects and provender. Chairman's address before the Council on Arteriosclerosis, American Heart Association, Dallas, Texas, November 12, 1969. Circulation. 1970 Apr;41(4):723-8.

27. Available at: http://consensus.nih.gov/1984/1984Cholesterol047html.htm. Accessed October 1, 2008.

28. Pritikin N. The Pritikin diet. JAMA. 1984 Mar 2;251(9):1160-1.

29. Barnard RJ, Lawani LO, Martin DA, et al. Effects of maturation and aging on the skeletal muscle glucose transport system. Am J Physiol. 1992 May;262(5 Pt 1):E619-26.

30. Roberts CK, Barnard RJ. Effects of exercise and diet on chronic disease. J Appl Physiol. 2005 Jan;98(1):3-30.

31. Hubbard JD, Inkeles S, Barnard RJ. Nathan Pritikin's heart. N Engl J Med. 1985 Jul 4;313(1):52.

32. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233-40.

33. Roberts CK, Chen AK, Barnard RJ. Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors. Atherosclerosis. 2007 Mar;191(1):98-106.

34. Roberts CK, Won D, Pruthi S, et al. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol. 2006 May;100(5):1657-65.

35. Roberts CK, Vaziri ND, Barnard RJ. Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability. Circulation. 2002 Nov 12;106(20):2530-2.

36. Anderson JW, Konz EC, Jenkins DJ. Health advantages and disadvantages of weight-reducing diets: a computer analysis and critical review. J Am Coll Nutr. 2000 Oct;19(5):578-90.

37. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA. 1981 Oct;78(10):6499-503.

38. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 1983 May;3(3):215-22.

39. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA. 1987 May;84(9):2995-8.

40. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26.

41. Ross R. The pathogenesis of atherosclerosis—an update. N Engl J Med. 1986 Feb 20;314(8):488-500.

42. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989 Oct;84(4):1086-95.

43. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915-24.

44. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995 May 1;91(9):2488-96.

45. Suits AG, Chait A, Aviram M, Heinecke JW. Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foam-cell formation. Proc Natl Acad Sci USA. 1989 Apr;86(8):2713-7.

46. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989 Feb;86(4):1372-6.

47. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006 Feb;83(2):456S-60S.

48. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998 Apr 17;93(2):241-52.

49. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med. 2008 May;263(5):517-27.

50. Zhang WZ, Venardos K, Finch S, Kaye DM. Detrimental effect of oxidized LDL on endothelial arginine metabolism and transportation. Int J Biochem Cell Biol. 2008;40(5):920-8.

51. Faloon W. A lethal misconception of epidemic proportion. Life Extension. 2007 May;13(5):7-14.

52. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005 Oct 12;294(14):1799-809.

53. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis—immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003 Sep;178(3):373-80.

54. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001 May 16;285(19):2481-5.

55. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA. 1991 Mar 1;88(5):1646-50.

56. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA. 1990 Jun;87(12):4879-83.

57. Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Mol Aspects Med. 1997;18(Suppl):S85-103.

58. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992 Jun 26;1126(3):247-54.

59. Kontush A, Hubner C, Finckh B, Kohlschutter A, Beisiegel U. Antioxidative activity of ubiquinol-10 at physiologic concentrations in human low density lipoprotein. Biochim Biophys Acta. 1995 Sep 14;1258(2):177-87.

60. Bowry VW, Mohr D, Cleary J, Stocker R. Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein. J Biol Chem. 1995 Mar 17;270(11):5756-63.

61. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004 Jun;23(3):423-33.

62. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-39.

63. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_16.pdf. Accessed October 15, 2008.

64. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20-8.

65. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999 Feb 16;99(6):779-85.

66. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty

acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008 Mar;197(1):12-24.

67. Pérez-Jiménez F, Ruano J, Perez-Martinez P, Lopez-Segura F, Lopez-Miranda J.

The influence of olive oil on human health: not a question of fat alone. Mol Nutr Food Res. 2007 Oct;51(10):1199-208.

68. Aviram M, Fuhrman B. Wine flavonoids protect against LDL oxidation and atherosclerosis. Ann NY Acad Sci. 2002 May;957:146-61.

69. Martin-Nizard F, Sahpaz S, Furman C, et al. Natural phenylpropanoids protect endothelial cells against oxidized LDL-induced cytotoxicity. Planta Med. 2003 Mar;69(3):207-11.

70. Janisch KM, Williamson G, Needs P, Plumb GW. Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Radic Res. 2004 Aug;38(8):877-84.

71. Sies H, Stahl W, Sevanian A. Nutritional, dietary and postprandial oxidative stress. J Nutr. 2005 May;135(5):969-72.

72. Mursu J, Voutilainen S, Nurmi T, et al. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Radic Biol Med. 2004 Nov 1;37(9):1351-9.

73. Baba S, Osakabe N, Kato Y, et al. Continuous intake of polyphenolic compounds containing cocoa powder reduces LDL oxidative susceptibility and has beneficial effects on plasma HDL-cholesterol concentrations in humans. Am J Clin Nutr. 2007 Mar;85(3):709-17.

74. Covas MI, Nyyssonen K, Poulsen HE, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006 Sep 5;145(5):333-41.

75. Baba S, Natsume M, Yasuda A, et al. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo- and hypercholesterolemic humans after intake of different levels of cocoa powder. J Nutr. 2007 Jun;137(6):1436-41.

76. Zern TL, Wood RJ, Greene C, et al. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr. 2005 Aug;135(8):1911-7.

77. Available at: http://www.doctorzebra.com/prez/z_x34mirx_g.htm#zree6#zree6. Accessed October 15, 2008.

78. Available at: http://www.nps.gov/archive/lyjo/ourheartshome/lbj3.htm. Accessed October 15, 2008.

Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.